Real-world study initiated to assess oral Semaglutide (Rybelsus®) efficacy in Swiss Type 2 Diabetes patients
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice
Abstract
A real-world, non-interventional study will assess oral Semaglutide (Rybelsus®) effectiveness in lowering blood sugar in Swiss Type 2 Diabetes patients over 8-10 months.